Showing results (211-220 of 322) with videos related to

Sort By:
Pageof 33
Blood Advances|January 4, 2018
Targeted deep sequencing in polycythemia vera and essential thrombocythemiaAyalew Tefferi, Terra L Lasho, Paola Guglielmelli, et al.
Blood|November 8, 2019
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanningJessica L Bridgford, Su Min Lee, Christine M M Lee, et al.
Blood|October 3, 2007
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective surveyMarco Ruggeri, Francesco Rodeghiero, Alberto Tosetto, et al.
Blood|November 1, 2013
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisFrancisco Cervantes, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.
Cancers|July 2, 2021
T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic MarkerMagda Zanelli, Giuseppe G Loscocco, Elena Sabattini, et al.
Blood|May 4, 2011
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patientsRobyn Scherber, Amylou C Dueck, Peter Johansson, et al.
The New England Journal of Medicine|January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
Blood|October 4, 2012
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)Tiziano Barbui, Guido Finazzi, Alessandra Carobbio, et al.
Leukemia|May 21, 2021
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
European Journal of Haematology|November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapyRuben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
Pageof 33